Management of antibody mediated rejection (AMR) in heart transplant patients: The real world in a French single center treating all pathological AMR

2021 ◽  
Author(s):  
Emmanuelle Vermes ◽  
Xavier Cansouline ◽  
Lucile Rouault ◽  
Marc Antoine May ◽  
Claudia Loardi
Keyword(s):  
Heart Transplant ◽  
Real World ◽  
Single Center ◽  
The Real ◽  
Antibody Mediated Rejection ◽  
Transplant Patients

scholarly journals Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tae-Hwan Kim ◽  
Hun Do Cho ◽  
Yong Won Choi ◽  
Hyun Woo Lee ◽  
Seok Yun Kang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Real World ◽  
Group Performance ◽  
Eastern Cooperative Oncology Group ◽  
Conversion Surgery ◽  
Single Center ◽  
Her2 Positive ◽  
Real World Data ◽  
World Data ◽  
The Real

Abstract Background Since the results of the ToGA trial were published, trastuzumab-based chemotherapy has been used as the standard first-line treatment for HER2-positive recurrent or primary metastatic gastric cancer (RPMGC). However, the real-world data has been rarely reported. Therefore, we investigated the outcomes of trastuzumab-based chemotherapy in a single center. Methods This study analyzed the real-world data of 47 patients with HER2-positive RPMGC treated with trastuzumab-based chemotherapy in a single institution. Results With the median follow-up duration of 18.8 months in survivors, the median overall survival (OS) and progression-free survival were 12.8 and 6.9 months, respectively, and the overall response rate was 64%. Eastern Cooperative Oncology Group performance status 2 and massive amount of ascites were independent poor prognostic factors for OS, while surgical resection before or after chemotherapy was associated with favorable OS, in multivariate analysis. In addition, 5 patients who underwent conversion surgery after chemotherapy demonstrated an encouraging median OS of 30.8 months, all with R0 resection. Conclusions Trastuzumab-based chemotherapy in patients with HER2-positive RPMGC in the real world demonstrated outcomes almost comparable to those of the ToGA trial. Moreover, conversion surgery can be actively considered in fit patients with a favorable response after trastuzumab-based chemotherapy.

Acute Myeloid Leukemia in the Real-World: Therapeutic Strategy and Outcome in a Single Center

2019 ◽  
Vol 19 ◽  
pp. S238
Author(s):  
Razan Mohty ◽  
Radwan Massoud ◽  
Zaher Chakhachiro ◽  
Rami Mahfouz ◽  
Samer Nassif ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Real World ◽  
Myeloid Leukemia ◽  
Therapeutic Strategy ◽  
Single Center ◽  
The Real ◽  
Acute Myeloid

Left ventricular endocardial pacing in the real world: Five years of experience at a single center

2019 ◽  
Vol 42 (6) ◽  
pp. 763-763
Author(s):  
Juan J. García Guerrero ◽  
Joaquín Fernández de la Concha Castañeda ◽  
Manuel Doblado Calatrava ◽  
Ángel Redondo Méndez ◽  
Manuel Lázaro Medrano ◽  
...  
Keyword(s):  
Real World ◽  
Left Ventricular ◽  
Years Of Experience ◽  
Single Center ◽  
The Real ◽  
Endocardial Pacing

Extended adherence of heart transplant patients – single-center study HDZ-NRW

2012 ◽  
Vol 60 (S 01) ◽  
Author(s):  
K Tigges-Limmer ◽  
G Schmid-Ott ◽  
U Schulz ◽  
Y Brocks ◽  
J Brakhage ◽  
...  
Keyword(s):  
Heart Transplant ◽  
Single Center ◽  
Transplant Patients ◽  
Single Center Study ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document